Corteva (CTVA) Q1 2026 earnings summary

Executive summary

• Q1 2026 delivered strong results with 11% net sales growth to $4.9B, 21% operating EBITDA growth, and 9% net income growth, driven by robust Seed and Crop Protection performance across all regions.

• Margin expansion was supported by price/mix gains, productivity actions, and lower input costs, with operating EBITDA margin rising to 29.3% (+240 bps YoY).

• The company reaffirmed full-year 2026 guidance, citing robust global demand, disciplined execution, and ongoing productivity benefits.

• Progress continued on the planned separation into two companies, with new leadership named, Form 10 filed, and separation targeted for Q4 2026.

• Major strategic actions included the announcement of Vylor as the new seed/genetics company and the launch of a restructuring program to align with the separation.

Financial highlights

• Net sales reached $4.9B (+11% YoY); organic sales up 7%; Seed net sales $3.02B (+12%), Crop Protection $1.88B (+10%).

• Operating EBITDA was $1.44B (+21% YoY), with margin up 240 basis points to 29.3%; operating EPS $1.50 (+33% YoY).

• GAAP net income from continuing operations was $725M (+9% YoY); GAAP EPS $1.07 (+10% YoY).

• Free cash flow was negative due to the Bayer settlement and seasonal working capital needs.

• $370M was returned to shareholders via share repurchases and dividends in Q1 2026.

Outlook and guidance

• Full-year 2026 operating EBITDA guidance is $4.0–$4.2B (7% growth at midpoint), margin 22–23%, and operating EPS $3.45–$3.70.

• $500M in share repurchases planned for the first half of 2026.

• The 2026 restructuring is expected to yield $115–$125M in annual run-rate savings by 2027.

• Guidance assumes no extreme weather, major operational disruptions, or significant macroeconomic shocks.

• Both companies are expected to maintain strong balance sheets and investment grade credit ratings post-separation.